Inducible No Synthase manufacturers
|
| | Inducible No Synthase Basic information |
| Product Name: | Inducible No Synthase | | Synonyms: | EC 1.14.13.39;INDUCIBLE NITRIC OXIDE SYNTHASE (MURINE RECOMBINANT);INDUCIBLE NITRIC OXIDE SYNTHASE (MURINE MACROPHAGE);INDUCIBLE NITRIC OXIDE SYNTHASE;INDUCIBLE NITRIC OXIDE SYNTHASE MOUSE;INOS;INOS, MOUSE MACROPHAGE;INOS, MOUSE, RECOMBINANT | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Inducible No Synthase Structure]() |
| | Inducible No Synthase Chemical Properties |
| storage temp. | −70°C | | form | buffered aqueous solution |
| | Inducible No Synthase Usage And Synthesis |
| Uses | Nitric Oxide Synthase, Inducible from mouse has been used in immunohistochemical studies. It is also used to evaluate the therapeutic efficacy of inducible nitric oxide synthase (NOS) on reperfusion-induced microcirculatory alterations and hemodynamic adverse effects in the microvasculature of skeletal muscle.
| | General Description | Inducible nitric oxide synthase (iNOS), also known as inflammatory nitric oxide synthase, is a calcium independent isoenzyme, involved in synthesis of nitric oxide (NO). It is a soluble enzyme encoded by the gene mapped to mouse chromosome 11. iNOS is active in dimeric form and its activity is induced by cytokines and various other stimuli. iNOS is expressed in various inflammatory conditions. | | Biochem/physiol Actions | Tumor-derived inducible nitric oxide synthase (iNOS) plays a vital role in stimulating tumor growth and vessel maturation. Therefore, it is considered to be a potential therapeutic target for anti-vascular cancer therapies. Unchecked activity of iNOS leads to overproduction of nitric oxide (NO), which is toxic for living cells. iNOS activity can be controlled at both transcription and translational level by regulating protein stability, dimerization, phosphorylation, cofactor binding and availability of oxygen and L-arginine as substrates. iNOS plays a vital role in excisional wound repair and exhibits gene therapy strategy to advance wound healing process in iNOS-deficient conditions such as diabetes and steroid treatment. |
| | Inducible No Synthase Preparation Products And Raw materials |
|